American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer

American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer
Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study a potential biomarker for metastatic prostate cancer, and determine how to best detect it. While some prostate cancers grow slowly and pose little threat to patients, others are rapidly-growing and spread quickly, leading to significantly poorer outcomes. Knowing which type of cancer a person has during the early stages would help doctors decide which treatment is most appropriate. However, no such biomarkers exist. "The big challenge in prostate cancer these days is to have a biomarker that will let the physician know whether to pursue watchful waiting because it's not metastatic, or to recommend radical treatment in order to shrink the tumor because it is likely to become metastatic," Wilma A. Hofmann, PhD, associate professor in the department of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB, said in a press release. "The critical issue is to find a prostate cancer biomarker that is reliable and sensitive, especially with low percentages of metastatic cancer cells, indicating the cancer progression is at an early stage," Hofmann added. In a joint study published last year in
Subscribe or to access all post and page content.